Phaseline

Companies › Brii Biosciences

Brii Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 10 registered trials: 9 Phase 2, 1 Phase 4; Infectious disease; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BRII-179
HBV therapeutic vaccine (T-cell activating immunotherapy)
–Phase 2For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) InfectionSep 2028
BRII-835 (VIR-2218, elebsiran)–Phase 2Chronic Hepatitis B Virus Infection; For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) InfectionSep 2028
Peginterferon Alfa-2A
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection; Chronic Hepatitis b; Chronic Hepatitis BSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05970289BRII-835 (VIR-2218, elebsiran)Phase 2Chronic Hepatitis B Virus InfectionInfectious diseaseJul 2025
NCT06491563BRII-179Phase 2For Treatment of Chronic Hepatitis B Virus InfectionInfectious diseaseAug 2026
NCT06491563BRII-835 (VIR-2218, elebsiran)Phase 2For Treatment of Chronic Hepatitis B Virus InfectionInfectious diseaseAug 2026
NCT06491563Peginterferon Alfa-2APhase 2For Treatment of Chronic Hepatitis B Virus InfectionInfectious diseaseAug 2026
NCT07573943Peginterferon Alfa-2APhase 4Chronic Hepatitis bInfectious diseaseDec 2026
NCT05771402Peginterferon Alfa-2APhase 2Chronic Hepatitis bInfectious diseaseDec 2026
NCT07845058Peginterferon Alfa-2APhase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT06650852BRII-179Phase 2Chronic Hepatitis B Virus (HBV) InfectionInfectious diseaseSep 2028
NCT06650852BRII-835 (VIR-2218, elebsiran)Phase 2Chronic Hepatitis B Virus (HBV) InfectionInfectious diseaseSep 2028
NCT06650852Peginterferon Alfa-2APhase 2Chronic Hepatitis B Virus (HBV) InfectionInfectious diseaseSep 2028

Targets

IFNAR1 (1) IFNAR2 (1)

Companies with the same targets

Diakonos Oncology PharmaEssentia BriaCell Therapeutics Xiamen Amoytop Biotech Biogen AstraZeneca Genrix (Shanghai) Biopharmaceutical

Companies built like this

CastleVax Medicago Eveliqure Biotechnologies Sanaria SIGA Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.